Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa, Double-Blind, Randomised, Parallel-Group, Multi-Centre Study to Evaluate the Analgesic Efficacy of 28 Days Oral Administration of AZD2066 Compared to Placebo in Peripheral Neuropathic Pain Patients With Mechanical Hypersensitivity.

Trial Profile

A Phase IIa, Double-Blind, Randomised, Parallel-Group, Multi-Centre Study to Evaluate the Analgesic Efficacy of 28 Days Oral Administration of AZD2066 Compared to Placebo in Peripheral Neuropathic Pain Patients With Mechanical Hypersensitivity.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 2066 (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Acronyms NP-MH
  • Sponsors AstraZeneca
  • Most Recent Events

    • 31 Aug 2012 Results presented at the 14th World Congress on Pain.
    • 28 Aug 2012 Primary endpoint 'Pain-intensity' has been met, based on results presented at 14th World Congress on Pain. However, due to termination of the study for safety reasons, only 87 of the planned 385 patients were enrolled.
    • 28 Aug 2012 Primary endpoint 'Numerical-Rating-Scale' has been met, based on results presented at 14th World Congress on Pain. However, due to termination of the study for safety reasons, only 87 of the planned 385 patients were enrolled.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top